Below analyst target — what the screen found 2026-10-16
Manufacturing dominates this screen, accounting for 32 of the 40 companies identified on October 15, 2026. The results are heavily concentrated in this sector rather than spread across the market.
Key figures
Data as of Oct 16, 2026- TVRD (Tvardi Therapeutics, Inc. Common Stock) market cap
- $14.01M
- CNTX (Context Therapeutics Inc. Common Stock) market cap
- $22.12M
- ALGS (Aligos Therapeutics, Inc. Common Stock) market cap
- $33.22M
- IBIO (iBio, Inc. Common Stock) market cap
- $50.37M
- CNTB (Connect Biopharma Holdings Limited Ordinary Shares) market cap
- $56.95M
- TENX (Tenax Therapeutics, Inc.) market cap
- $57.45M
Manufacturing dominates this screen, accounting for 32 of the 40 companies¹˒² identified on October 15, 2026. The results are heavily concentrated in this sector rather than spread across the market.
Among those appearing are several small-cap names: Tvardi Therapeutics (TVRD) at $14.01M³, Context Therapeutics (CNTX) at $22.12M⁴, Aligos Therapeutics (ALGS) at $33.22M⁵, iBio (IBIO) at $50.37M⁶, Connect Biopharma Holdings (CNTB) at $56.95M⁷, and Tenax Therapeutics (TENX) at $57.45M. All these companies belong to the Manufacturing sector.
Every company in this group passes a single test: they are trading well under a well-covered consensus analyst target. This indicates a gap where the crowd disagrees with the current tape. Because analyst targets are rarely revised, a large gap often reflects a price drop rather than an increase in analyst bullishness.
Passing this test does not establish that a company is worth owning. The screen is a filter, not a verdict, and it provides no evidence regarding forward returns. None of the six tracked macro signals are currently risk-off, but the screen only confirms that these specific numbers aligned on a single date.
Educational tool. Not investment advice. This article was produced with automated assistance. Every figure in it was checked against the underlying data before it was published; the interpretation was not.